Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

India's Adani Green Energy plans to spend 310 billion rupees ($3.64 billion) in capital expenditure to add 5 gigawatts of ...

Recent health news highlights include Sandoz's criticism of EU drug pricing, a US-Mexico pact on pest control, advancements in cancer therapies, and significant corporate deals. Studies, policy ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.